Pharmaceutical Executive June 6, 2024
Acquisition of Elsie Biotechnologies is expected to strengthen GSK’s research capabilities in modulating gene expression through the use of oligonucleotide.
GSK has acquired Elsie Biotechnologies, a biotech firm specializing in oligonucleotide therapeutics, in a deal that could reach up to $50 million. Known for possessing the ability to modulate gene expression, oligonucleotide can support targets that traditional drugs cannot reach, according to GSK. They added that the acquisition will enable the integration of Elsie’s technologies with GSK’s artificial intelligence (AI) and machine learning (ML) expertise to accelerate the development of oligonucleotide drugs for challenging diseases.1
“We have already made great strides in oligonucleotide drug development through our work in chronic hepatitis B and steatotic liver disease and are thrilled to...
Today's Sponsors
Today's Sponsor